# Repligen Corp: overview

RGEN · Nasdaq · CIK 730272 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rgen.md) · [Financials](/companies/rgen/financials.md) · [Filings](/companies/rgen/filings.md) · [Insiders](/companies/rgen/insiders.md)

Latest reported revenue: [$204.1m](/filings/0001193125-26-323773.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001193125-26-323773).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [155](/filings/0001193125-25-264666.md) | [168 d](/filings/0001193125-26-076528.md) | [169](/filings/0001193125-26-208954.md) | [182](/filings/0001193125-26-323773.md) | [189](/filings/0001193125-25-264666.md) | [198 d](/filings/0001193125-26-076528.md) | [194](/filings/0001193125-26-208954.md) | [204](/filings/0001193125-26-323773.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(5.1%)](/filings/0001193125-25-264666.md) | [(21.8%) d](/filings/0001193125-26-076528.md) | [3.9%](/filings/0001193125-26-208954.md) | [7.6%](/filings/0001193125-26-323773.md) | [8.9%](/filings/0001193125-25-264666.md) | [9.0% d](/filings/0001193125-26-076528.md) | [8.2%](/filings/0001193125-26-208954.md) | [6.8%](/filings/0001193125-26-323773.md) |
| Net margin | % | [(0.4%)](/filings/0001193125-25-264666.md) | [(20.2%) d](/filings/0001193125-26-076528.md) | [3.4%](/filings/0001193125-26-208954.md) | [8.2%](/filings/0001193125-26-323773.md) | [7.9%](/filings/0001193125-25-264666.md) | [6.7% d](/filings/0001193125-26-076528.md) | [4.3%](/filings/0001193125-26-208954.md) | [2.5%](/filings/0001193125-26-323773.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001193125-25-264666.md) | not reported | [0.10](/filings/0001193125-26-208954.md) | [0.26](/filings/0001193125-26-323773.md) | [0.26](/filings/0001193125-25-264666.md) | not reported | [0.15](/filings/0001193125-26-208954.md) | [0.09](/filings/0001193125-26-323773.md) |
| Free cash flow | $m | [42.3 d](/filings/0001193125-25-264666.md) | [33.6 d](/filings/0001193125-26-076528.md) | [11.4](/filings/0001193125-26-208954.md) | [21.5 d](/filings/0001193125-26-323773.md) | [43.4 d](/filings/0001193125-25-264666.md) | [17.6 d](/filings/0001193125-26-076528.md) | [23.6](/filings/0001193125-26-208954.md) | [27.4 d](/filings/0001193125-26-323773.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [671](/filings/0000950170-24-127842.md) | [802](/filings/0000950170-25-038999.md) | [632](/filings/0001193125-26-076528.md) | [634](/filings/0001193125-26-076528.md) | [738](/filings/0001193125-26-076528.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [24.9%](/filings/0000950170-24-127842.md) | [28.0%](/filings/0000950170-25-038999.md) | [7.5%](/filings/0001193125-26-076528.md) | [(5.5%)](/filings/0001193125-26-076528.md) | [7.5%](/filings/0001193125-26-076528.md) |
| Net margin | % | [19.1%](/filings/0000950170-24-127842.md) | [23.2%](/filings/0000950170-25-038999.md) | [5.6%](/filings/0001193125-26-076528.md) | [(4.0%)](/filings/0001193125-26-076528.md) | [6.6%](/filings/0001193125-26-076528.md) |
| Diluted EPS | $ per share | [2.24](/filings/0000950170-24-127842.md) | [3.24](/filings/0000950170-25-038999.md) | [0.63](/filings/0001193125-26-076528.md) | [(0.46)](/filings/0001193125-26-076528.md) | [0.86](/filings/0001193125-26-076528.md) |
| Free cash flow | $m | [51.9](/filings/0000950170-24-127842.md) | [87.2](/filings/0000950170-25-038999.md) | [77.7](/filings/0001193125-26-076528.md) | [150](/filings/0001193125-26-076528.md) | [93.9](/filings/0001193125-26-076528.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rgen/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $734.7m | 5,384,938 |  | Reduced −608,116 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $453.9m | 3,326,690 |  | Added +439,904 |
| [UNITED CAPITAL FINANCIAL ADVISORS, LLC](/funds/1463217.md) | 2026-06-30 | $380.8m | 2,790,650 |  | Added +16,670 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $329.0m | 2,411,171 |  | Added +14,660 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $315.6m | 2,312,825 |  | Added +7,731 |
| [MAVERICK CAPITAL LTD](/funds/934639.md) | 2026-06-30 | $270.8m | 1,984,554 |  | Added +465,749 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $245.7m | 1,800,530 |  | Added +23,245 |
| [MASSACHUSETTS FINANCIAL SERVICES CO /MA/](/funds/912938.md) | 2026-06-30 | $220.6m | 1,617,021 |  | Added +219,506 |
| [WASATCH ADVISORS LP](/funds/814133.md) | 2026-06-30 | $217.0m | 1,590,251 |  | Added +346,720 |
| [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $215.0m | 1,576,132 |  | Added +650,918 |

## Recent filings

[All 1,047 filings](/companies/rgen/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-30 | 16:01 ET | [10-Q](/filings/0001628280-26-068562.md) | Quarterly report, period 2026-09-30 | 0001628280-26-068562 |
| 2026-10-30 | 06:04 ET | [8-K](/filings/0001628280-26-068382.md) | 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-068382 |
| 2026-10-27 | 07:04 ET | [8-K](/filings/0001628280-26-067405.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-067405 |
| 2026-10-06 | 09:14 ET | [8-K](/filings/0001193125-26-415015.md) | 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-415015 |
| 2026-09-15 | 16:04 ET | [8-K](/filings/0001628280-26-062043.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-062043 |
| 2026-09-08 | 17:26 ET | [8-K](/filings/0001193125-26-385380.md) | 8.01 Other events | 0001193125-26-385380 |
| 2026-07-29 | 16:19 ET | [10-Q](/filings/0001193125-26-323773.md) | Quarterly report, period 2026-06-30 | 0001193125-26-323773 |
| 2026-07-28 | 07:13 ET | [8-K](/filings/0001193125-26-318853.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-318853 |
| 2026-07-22 | 08:56 ET | [8-K](/filings/0001193125-26-311402.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-311402 |
| 2026-05-15 | 08:09 ET | [8-K](/filings/0001193125-26-225380.md) | 5.07 Shareholder vote results | 0001193125-26-225380 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076528.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/7992aeca-8108-4c94-a997-59ca293aee14)

## About the filer

- CIK: 730272
- Tickers: RGEN
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:08 ET. No prices; not investment advice.